Skip to content


Investor FAQs


Atara Biotherapeutics was founded in August 2012.

Atara Biotherapeutics was incorporated in the state of Delaware in August 2012.

611 Gateway Blvd, Suite 900
South San Francisco, CA 94080
(650) 278-8930

December 31st

Deloitte & Touche LLP

Atara Biotherapeutics is traded on the NASDAQ stock exchange under the symbol “ATRA”.

Atara Biotherapeutics went public on October 15, 2014.

Shares can be purchased through a stockbroker of your choice.

Atara Biotherapeutics does not offer a direct stock purchase plan.

Currently, Atara Biotherapeutics does not offer a dividend or a dividend reinvestment program.

046513 107

Computershare Trust Company, N.A.

Correspondence should be mailed to:

P.O. Box 505000 
Louisville, KY  40233

Overnight correspondence should be sent to: 

462 South 4th Street, Suite 1600
Louisville, KY 40202

(877) 373-6374 (U.S., Canada and Puerto Rico)
(781) 575-2879 (non-U.S.)

Email: (please include a reference to “Atara Biotherapeutics”)

Please contact our transfer agent, Computershare Trust Company, N.A.

For media inquiries please send an email to

For investor related questions please send an email using the “Contact Us” section on our investor relations website.

Please visit the “Investor Relations” section of our investor relations website and choose the "Email Alerts" button to be added to the Atara Biotherapeutics distribution list.

Electronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:

Atara Biotherapeutics, Inc.
Attn: Investor Relations
611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080


Please submit your question using the form below.

Contact Form
* Indicates required field